ICx Technologies Acquires GHC Technologies

WASHINGTON, Jan. 16 /PRNewswire/ -- ICx Technologies, a provider of advanced technology solutions for homeland and military security, has acquired GHC Technologies, a developer of technologies for rapid molecular detection. This acquisition provides ICx with leading edge technologies to be integrated into its next generation biodetection products and solutions. The added expertise will also allow ICx to provide extremely fast and highly accurate detection of bioagents to military and security agencies at a low cost.

ICx currently offers a strong line of products to help reduce the vulnerability of individuals and assets to biological threats. Such products include a biological "smoke alarm" that continuously monitors for indoor hazards by assessing changes in ambient air biological particulate levels. ICx plans to incorporate GHC technologies into its existing product line as well as in current and future research and development projects in order to provide integrated biodefense solutions.

"GHC is a leader in adapting high performance laboratory assays to meet the demanding requirements of real world security applications. They are currently funded by DHS on a number of important biosensing programs, such as a rapid pathogen detector for building security and a highly sensitive pathogen reporter for city-wide surveillance," said David Cullin, ICx Senior Vice President of Technology Transition. "ICx is remarkably adept at bringing advanced technologies to the market quickly. The GHC technology will be rapidly integrated into our biodefense solutions targeted at sensing harmful bioagaents in buildings, transportation terminals and public arenas, as well as for frontline military applications."

Current ICx biodefense products include biosamplers and biotriggers which are deployed at first responder sites, fire departments and critical DoD and commercial buildings. These biological "smoke alarm" products provide the first line of defense against airborne bioagents. The technologies developed by GHC round out the product line to include rapid, highly specific detection and identification of biological warfare agents such as Anthrax and will ultimately allow ICx to accurately and affordably identify such agents on the frontline.

"We are excited to join the growing ICx team," said Dr. Roland Stoughton, CEO of GHC. "We see very strong synergies with the existing ICx products and systems and a clear path to fielding our technology."

About ICx Technologies(TM)

ICx develops advanced technologies for effective security solutions. ICx sensors detect and identify chemical, biological, radiological and explosive (CBRNE) materials. ICx surveillance products discern people and objects invisible to human senses and conventional cameras. ICx software and systems connect, command and control these security devices, while its intelligence and special-operations experts provide the unique insight that drives the company's innovation. ICx has manufacturing and research facilities in the United States, Canada and Europe. http://www.icxt.com

About GHC Technologies(TM)

GHC develops technologies for rapid and information-rich molecular diagnosis. The company's research and development efforts are strengthening U.S. biodefense preparedness and enabling commercial partners to bring ambitious clinical diagnostic products to market. GHC began operations in 2004 and has offices and laboratories in La Jolla, CA.

All trademarks, registered trademarks and service marks are the property of their respective owners.

CONTACT: Matthew Langan, +1-202-298-7600, ext 219, F: +1-202-298-9050,matthew@dbcpr.com, for ICx Technologies

Web site: http://www.icxt.com/